Skip to main
LENZ

LENZ Stock Forecast & Price Target

LENZ Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LENZ Therapeutics has completed a comprehensive clinical program, including three Phase 3 trials within the CLARITY program, demonstrating strong efficacy and safety that supports a competitive market position in treating presbyopia. The company's strong clinical results are expected to catalyze growth in annual revenues, particularly as it plans to enlarge its sales force in response to positive outcomes. Moreover, projections indicate that LENZ is on track to achieve profitability by 2028, highlighting its financial viability and potential for long-term success in the biopharmaceutical market.

Bears say

LENZ Therapeutics, Inc. faces significant commercial challenges in altering long-standing consumer behavior relating to presbyopia, restricting its potential market success. The company’s limited product pipeline, with no diversification beyond its flagship product Vizz, raises concerns about its long-term viability and ability to leverage commercial infrastructure effectively. Furthermore, competitive pressures from alternative presbyopia treatments, along with potential generic challenges to Vizz and the need for additional funding or strategic partnerships, contribute to the negative outlook on the company's stock performance.

LENZ has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LENZ Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LENZ Therapeutics Inc (LENZ) Forecast

Analysts have given LENZ a Buy based on their latest research and market trends.

According to 4 analysts, LENZ has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LENZ Therapeutics Inc (LENZ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.